Stem Cell Transplantation for Patients With Multiple Myeloma

Phase 1 Completed 30 enrolled University of Chicago

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).

Timeline

Start: 2011-07-12
Primary completion: 2024-08-28
Completion: 2024-08-28

Publications

Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, Kline J. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 Jan;8(1):e000286. doi: 10.1136/jitc-2019-000286.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Basiliximab	Monoclonal antibody	20 mg	Intravenous
Background	G-CSF	Unknown	—	Subcutaneous
Background	Melphalan	Small molecule	100 mg/m2	—
Background	Plerixafor	Small molecule	—	—

Stem Cell Transplantation for Patients With Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications